Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M
Swiss pharmaceutical giant Novartis is buying European company Calypso Biotech in a deal that could be worth up to $375 million, according to an announcement from Calypso on Monday, marking one...To view the full article, register now.
Already a subscriber? Click here to view full article